Table 1.
Technological characteristics of the two FDA-approved cfDNA NGS. SNV: single-nucleotide variant, TMB: tumor mutational burden, LoD: limit of detection, G360: Guardant360® CDx, F1LCDx: FoundationOne® Liquid CDx.
| Characteristics | G360 | F1LCDx | |
|---|---|---|---|
| Starting material | Whole blood | 2 × 8.5 mL | 2 × 10 mL |
| Alterations types | SNV | 73 genes | 311 genes |
| Copy number variations | 18 genes (amplification only) | 310 genes | |
| Fusions/Rearrangements | 8 genes | 324 genes | |
| Microsatellite status | Yes | Yes | |
| TMB | No | Yes | |
| Turnaround time | Announced | 7 calendar days | Less than 2 weeks |
| LoD | SNV-indels 95–100% | 0.20–0.25% | 0.4–0.82% |
| Fusions/Rearrangements | 0.20% | 0.37–0.90% | |
| Tumor fraction | No | Yes |